Trever G. Bivona

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Immunohistochemistry to Study YAP in Human Tissue Samples.

Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.

Polytherapy and Targeted Cancer Drug Resistance.

Dampening oncogenic RAS signaling.

Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Targeting Oncogenic BRAF: Past, Present, and Future.

Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.

Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.

Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.

Stepwise evolution of therapy resistance in AML.

Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.